Alessia di Coste

Ms. Alessia di Coste

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2023 in Biomedicines
Verified
Journal Article
Open access
Paola ZanettaPaola Zanetta
Paola Zanetta
Diletta SquarzantiDiletta Squarzanti
Diletta Squarzanti
ACAlessia di Coste
Alessia di Coste
AAAngela Amoruso
Angela Amoruso
MPMarco Pane
Marco Pane
Barbara AzzimontiBarbara Azzimonti
Barbara Azzimonti
Fusobacterium nucleatum and Porphyromonas gingivalis human periodontopathogens play a leading part in oral squamous cell carcinoma through cell proliferation, invasion, and persistent inflammation promotion and maintenance. To explore how the activity of Lactobacillus-derived cell-free supernatants (CFSs) can be influenced by growth medium components, CFSs were produced both in the standard MRS and the novel animal-derivative-free “Terreno Industriale Lattobacilli” (TIL) media, and in vitro screened for the containment of F. nucleatum and P. gingivalis both single and co-cultured and also for the interference on their co-aggregation. The viability assay demonstrated that the Limosilactobacillus reuteri LRE11 and Ligilactobacillus salivarius LS03 MRS-produced CFSs were significantly more effective against single and co-cultured pathogens. All the other CFSs significantly improved their efficacy when produced in TIL. Both MRS- and TIL-produced CFSs significantly inhibited the single and co-cultured pathogen biofilm formation. Only Levilactobacillus brevis LBR01 CFS in MRS specifically reduced F. nucleatum and P. gingivalis co-aggregation, while viable LBR01, LS03, and LRE11 in MRS significantly co-aggregated with the pathogens, but only LS03 cultivated in TIL improved this effect. This work paves the way to better consider environmental growth conditions when screening for probiotic and postbiotic efficacy as crucial to pathogen aggregation, adhesion to the host’s niches, and exclusion.

11 February 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
CVChiara Venegoni
Chiara Venegoni
STSilvia Tortorella
Silvia Tortorella
ACAlessandra Caliendo
Alessandra Caliendo
ILIrene Locatelli
Irene Locatelli
ACAlessia di Coste
Alessia di Coste
MAMassimo Alfano
Massimo Alfano
The limitations of current diagnostic imaging techniques and therapies for bladder cancer are associated with and responsible for the recurrence and progression of residual disease, with an impact on social costs and quality of life of patients. This study delivers a cost‐effective solution for the detection of bladder cancer residual disease, which is represented by the early detection of bladder cancer lesions < 1 mm. Urine‐stable 34‐mer SH‐terminated 2′F‐Py‐RNA aptamer that recognizes the integrin α5β1, expressed by 81% of human high‐grade non‐muscle invasive bladder cancer, is developed. The intravesical instillation of aptamer‐conjugated gold nanorods as contrast agent for photoacoustic imaging is validated in a preclinical model of orthotopic bladder cancer expressing the integrin α5β1. The photoacoustic signal of gold nanorods remains on the tumor surface for 3 h and allows early detection of cancer lesions < 1 mm. The aptamer is internalized into lysosomes, an opportunity that paves the way for lysosomal‐mediated drug release in tumor cells. This study highlights the potential of urine‐stable aptamer for the delivery of a solution to target the residual high‐grade bladder cancer disease.

Verified
Journal Article
Open access
PDF file
Paola ZanettaPaola Zanetta
Paola Zanetta
Diletta SquarzantiDiletta Squarzanti
Diletta Squarzanti
ACAlessia di Coste
Alessia di Coste
RRRoberta Rolla
Roberta Rolla
Paolo Aluffi VallettiPaolo Aluffi Valletti
Paolo Aluffi Valletti
Barbara AzzimontiBarbara Azzimonti
Barbara Azzimonti
The human oral pathobionts Aggregatibacter actinomycetemcomitans, Streptococcus mitis and Streptococcus mutans, in dysbiosis-promoting conditions, lead to oral infections, which also represent a threat to human systemic health. This scenario may be worsened by antibiotic misuse, which favours multi-drug resistance, making the research on pathogen containment strategies more than crucial. Therefore, we aimed to in vitro select the most promising probiotic strains against oral pathogen growth, viability, biofilm formation, and co-aggregation capacity, employing both the viable probiotics and their cell-free supernatants (CFSs). Interestingly, we also assessed probiotic efficacy against the three-pathogen co-culture, mimicking an environment similar to that in vivo. Overall, the results showed that Lactobacillus CFSs performed better than the Bifidobacterium, highlighting Limosilactobacillus reuteri LRE11, Lacticaseibacillus rhamnosus LR04, Lacticaseibacillus casei LC04, and Limosilactobacillus fermentum LF26 as the most effective strains, opening the chance to deeper investigation of their action and CFS composition. Altogether, the methodologies presented in this study can be used for probiotic efficacy screenings, in order to better focus the research on a viable probiotic, or on its postbiotics, suitable in case of infections.